Inquis Medical, a trailblazer in medical technology focused on next-generation thrombectomy systems, has closed a $40 million Series B financing round led by Marshall Wace. The funds will accelerate the commercialization of the Aventus Precision Thrombectomy System™, featuring tissue-sensing technology that enables operators to gain real-time insights into tissue composition, offering unprecedented precision during thrombectomy procedures.
The Aventus system, cleared by the FDA for peripheral uses earlier this year, is currently in an Investigational Device Exemption (IDE) pivotal trial targeting pulmonary embolism (PE) patients. With commercialization expected in 2025, the new capital will support Inquis Medical’s IDE study completion and expand its proprietary technology.
“This funding validates investor confidence in our mission and the transformative potential of our technology,” said Vahid Saadat, Co-CEO of Inquis Medical. Co-CEO Mojgan Saadat added, “We’re thrilled to advance our goal of enhancing patient care with our unique technology.” Andrew D. Goldberg, MD, from Marshall Wace, joins the Inquis Board as part of this funding round.
With venous thromboembolism (VTE) affecting up to 900,000 people annually in the U.S., Inquis Medical’s innovations aim to address the limitations of current thrombectomy systems, reducing blood loss and enhancing procedural efficiency in PE treatment.
